vs
Side-by-side financial comparison of Datadog (DDOG) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.
BeOne Medicines Ltd. is the larger business by last-quarter revenue ($1.5B vs $953.2M, roughly 1.6× Datadog). Datadog runs the higher net margin — 4.9% vs 4.4%, a 0.4% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs 29.2%). BeOne Medicines Ltd. produced more free cash flow last quarter ($379.8M vs $318.2M). Over the past eight quarters, BeOne Medicines Ltd.'s revenue compounded faster (41.2% CAGR vs 24.9%).
Datadog, Inc. is an American company that provides an observability service for cloud-scale applications, providing monitoring of servers, databases, tools, and services, through a SaaS-based data analytics platform. Founded and headquartered in New York City, the company is a publicly traded entity on the Nasdaq stock exchange.
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
DDOG vs ONC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $953.2M | $1.5B |
| Net Profit | $46.6M | $66.5M |
| Gross Margin | 80.4% | 90.5% |
| Operating Margin | 1.0% | 12.4% |
| Net Margin | 4.9% | 4.4% |
| Revenue YoY | 29.2% | 32.8% |
| Net Profit YoY | 2.1% | 143.8% |
| EPS (diluted) | $0.13 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $953.2M | $1.5B | ||
| Q3 25 | $885.7M | $1.4B | ||
| Q2 25 | $826.8M | $1.3B | ||
| Q1 25 | $761.6M | $1.1B | ||
| Q4 24 | $737.7M | $1.1B | ||
| Q3 24 | $690.0M | $1.0B | ||
| Q2 24 | $645.3M | $929.2M | ||
| Q1 24 | $611.3M | $751.7M |
| Q4 25 | $46.6M | $66.5M | ||
| Q3 25 | $33.9M | $124.8M | ||
| Q2 25 | $2.6M | $94.3M | ||
| Q1 25 | $24.6M | $1.3M | ||
| Q4 24 | $45.6M | $-151.9M | ||
| Q3 24 | $51.7M | $-121.3M | ||
| Q2 24 | $43.8M | $-120.4M | ||
| Q1 24 | $42.6M | $-251.2M |
| Q4 25 | 80.4% | 90.5% | ||
| Q3 25 | 80.1% | 86.1% | ||
| Q2 25 | 79.9% | 87.5% | ||
| Q1 25 | 79.3% | 85.2% | ||
| Q4 24 | 80.5% | 85.8% | ||
| Q3 24 | 80.0% | 83.0% | ||
| Q2 24 | 80.9% | 85.1% | ||
| Q1 24 | 82.0% | 83.4% |
| Q4 25 | 1.0% | 12.4% | ||
| Q3 25 | -0.7% | 11.5% | ||
| Q2 25 | -4.3% | 6.7% | ||
| Q1 25 | -1.6% | 1.0% | ||
| Q4 24 | 1.3% | -7.0% | ||
| Q3 24 | 2.9% | -12.0% | ||
| Q2 24 | 2.0% | -11.5% | ||
| Q1 24 | 2.0% | -34.8% |
| Q4 25 | 4.9% | 4.4% | ||
| Q3 25 | 3.8% | 8.8% | ||
| Q2 25 | 0.3% | 7.2% | ||
| Q1 25 | 3.2% | 0.1% | ||
| Q4 24 | 6.2% | -13.5% | ||
| Q3 24 | 7.5% | -12.1% | ||
| Q2 24 | 6.8% | -13.0% | ||
| Q1 24 | 7.0% | -33.4% |
| Q4 25 | $0.13 | $0.05 | ||
| Q3 25 | $0.10 | $0.08 | ||
| Q2 25 | $0.01 | $0.06 | ||
| Q1 25 | $0.07 | $0.00 | ||
| Q4 24 | $0.14 | $-0.10 | ||
| Q3 24 | $0.14 | $-0.09 | ||
| Q2 24 | $0.12 | $-0.09 | ||
| Q1 24 | $0.12 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $401.3M | $4.5B |
| Total DebtLower is stronger | — | $836.4M |
| Stockholders' EquityBook value | $3.7B | $4.4B |
| Total Assets | $6.6B | $8.2B |
| Debt / EquityLower = less leverage | — | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $401.3M | $4.5B | ||
| Q3 25 | $540.6M | $4.0B | ||
| Q2 25 | $489.0M | $2.8B | ||
| Q1 25 | $1.1B | $2.5B | ||
| Q4 24 | $1.2B | $2.6B | ||
| Q3 24 | $337.4M | $2.7B | ||
| Q2 24 | $411.0M | $2.6B | ||
| Q1 24 | $282.2M | $2.8B |
| Q4 25 | — | $836.4M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $3.7B | $4.4B | ||
| Q3 25 | $3.4B | $4.1B | ||
| Q2 25 | $3.2B | $3.8B | ||
| Q1 25 | $2.9B | $3.5B | ||
| Q4 24 | $2.7B | $3.3B | ||
| Q3 24 | $2.6B | $3.4B | ||
| Q2 24 | $2.4B | $3.4B | ||
| Q1 24 | $2.2B | $3.4B |
| Q4 25 | $6.6B | $8.2B | ||
| Q3 25 | $6.1B | $7.6B | ||
| Q2 25 | $5.8B | $6.3B | ||
| Q1 25 | $6.0B | $5.8B | ||
| Q4 24 | $5.8B | $5.9B | ||
| Q3 24 | $4.6B | $5.8B | ||
| Q2 24 | $4.4B | $5.7B | ||
| Q1 24 | $4.1B | $5.7B |
| Q4 25 | — | 0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $327.1M | $417.3M |
| Free Cash FlowOCF − Capex | $318.2M | $379.8M |
| FCF MarginFCF / Revenue | 33.4% | 25.4% |
| Capex IntensityCapex / Revenue | 0.9% | 2.5% |
| Cash ConversionOCF / Net Profit | 7.02× | 6.28× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $941.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $327.1M | $417.3M | ||
| Q3 25 | $251.5M | $402.6M | ||
| Q2 25 | $200.1M | $263.6M | ||
| Q1 25 | $271.5M | $44.1M | ||
| Q4 24 | $265.2M | $75.2M | ||
| Q3 24 | $228.7M | $188.4M | ||
| Q2 24 | $164.4M | $-95.6M | ||
| Q1 24 | $212.3M | $-308.6M |
| Q4 25 | $318.2M | $379.8M | ||
| Q3 25 | $234.7M | $354.5M | ||
| Q2 25 | $184.9M | $219.8M | ||
| Q1 25 | $262.8M | $-12.3M | ||
| Q4 24 | $257.5M | $-17.3M | ||
| Q3 24 | $220.3M | $54.7M | ||
| Q2 24 | $160.0M | $-205.5M | ||
| Q1 24 | $198.1M | $-465.1M |
| Q4 25 | 33.4% | 25.4% | ||
| Q3 25 | 26.5% | 25.1% | ||
| Q2 25 | 22.4% | 16.7% | ||
| Q1 25 | 34.5% | -1.1% | ||
| Q4 24 | 34.9% | -1.5% | ||
| Q3 24 | 31.9% | 5.5% | ||
| Q2 24 | 24.8% | -22.1% | ||
| Q1 24 | 32.4% | -61.9% |
| Q4 25 | 0.9% | 2.5% | ||
| Q3 25 | 1.9% | 3.4% | ||
| Q2 25 | 1.8% | 3.3% | ||
| Q1 25 | 1.1% | 5.0% | ||
| Q4 24 | 1.1% | 8.2% | ||
| Q3 24 | 1.2% | 13.3% | ||
| Q2 24 | 0.7% | 11.8% | ||
| Q1 24 | 2.3% | 20.8% |
| Q4 25 | 7.02× | 6.28× | ||
| Q3 25 | 7.42× | 3.22× | ||
| Q2 25 | 75.58× | 2.79× | ||
| Q1 25 | 11.02× | 34.71× | ||
| Q4 24 | 5.82× | — | ||
| Q3 24 | 4.42× | — | ||
| Q2 24 | 3.75× | — | ||
| Q1 24 | 4.98× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DDOG
| North America | $678.7M | 71% |
| International | $274.5M | 29% |
ONC
Segment breakdown not available.
